Antipsychotic Use and the risk of rhabdomyolysis

Journal of Pharmacy Practice

Volumn 27, Issue 5, 2014, Pages 501-512

  Packard, Kathleen ^a   Price, Paul ^a   Hanson, Ashley ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

adverse drug reaction; antipsychotic; psychiatry

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; ILLICIT DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; ALCOHOL WITHDRAWAL; ARTICLE; DEHYDRATION; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG INTOXICATION; FALLING; FEMALE; HUMAN; IMMOBILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SEIZURE; UNITED STATES; AGED; BLOOD; BODY TEMPERATURE; CHEMICALLY INDUCED; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY TEMPERATURE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RHABDOMYOLYSIS; RISK FACTORS; UNITED STATES;

EID: 84904432531     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013516509     Document Type: Article

References (64)

1. National Institute of Mental Health. Statistics. http://www.nimh.nih.gov/statistics/index.shtml. Accessed May 1, 2013.
2. Medco. America's State of Mind; 2011.http://apps.who.int/medicinedocs/documents/s19032en/s19032en.pdf. Accessed June 20, 2013.
3. IMS Health MIDAS; December 2011.http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top-20-Global-Products.pdf. Accessed May 1, 2013.
4. Stagnitti MN Trends in Antipsychotic Purchases and Expenses for the US Civilian Noninstitutionalized Population, 1997 and 2007. MEPS Medical Expenditure Panel Survey. Rockville, MD: AHRQ - Agency for Healthcare Research and Quality ; 2010:
5. Zaidi AN. Rhabdomyolysis after correction of hyponatremia in psychogenic polydipsia possibly complicated by ziprasidone. Ann Pharmacother. 2005 ; 39 (10). 1726-1731
6. Conforti A, Chiamulera C, Moretti U, et al. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf. 2007 ; 2 (1). 47-63
7. Bienvenu OJ, Neufeld KJ, Needham DM. Treatment for four psychiatric emergencies in the intensive care until. Crit Care Med. 2012 ; 40 (9). 2662-2670
8. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982 ; 61 (3). 141-152
9. Wilhelm K, Curtis J, Birkett V, et al. The clinical significance of serial creatine phosphokinase estimations in acute ward admissions. Aust N Z J Psychiatry. 1994 ; 28 (3). 453-457
10. Maniam T, Rahman MA. All elevated creatine kinase is not neuroleptic malignant syndrome. Med J Malaysia. 1994 ; 49 (3). 252-254
11. Cavanaugh JJ, Finlayson RE. Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J Clin Psychiatry. 1984 ; 45 (8). 356-357
12. Meltzer HY, Eklum L, Moline RA. Serum-enzyme changes in newly-admitted psychiatric patients. Arch Gen Psych. 1969 ; 21 (6). 731-738
13. Tsoi WF, Candlish JK, Kua EH. Creatine phosphokinase and schizophrenia in Singapore. Ann Acad Med. 1985 ; 14 (1). 84-86
14. Geizer M, Ancill RJ. Does combined neuroleptic-electroconvulsive therapy treatment increase the likelihood of creatine phosphokinase rise?. Can J Psychiatry. 1997 ; 42 (1). 88
15. Egan MF, Dargham AA, Kirch DG, et al. Serum creatine phosphokinase elevations in patients with tardive dyskinesia. Br J Psychiatry. 1993 ; 162: 551-553
16. Rafool GJ. Causes of rhabdomyolysis. Mayo Clin Proc. 1995 ; 70 (12). 1225
17. Rizzieri DA. Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia. Mayo Clin Proc. 1995 ; 70 (5). 473-476
18. Akkaya C, Sarandol A, Sivrioglu EY, et al. A patient using ziprasidone with polydipsia, seizure, hyponatremia, and rhabdomyolysis. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30 (8). 1535-1538
19. Tenyi T, Voros V. Successful switch to olanzapine after rhabdomyolysis caused by water intoxication and clozapine use. Pharmacopsychiatry. 2006 ; 39 (4). 157-158
20. Wicki J, Rutschmann OT, Burri H, et al. Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine. Ann Pharmacol. 1008 ; 32 (9). 892-895
21. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacol. 1996 ; 15 (4). 395-405
22. Devarajan S, Dursun SM. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacol. 2000 ; 152 (1). 122
23. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy, and tolerability. Drugs. 2008 ; 68 (16). 2269-2292
24. Miller KM, Holliday KL Pharmacotherapy Self-Assessment Program, 7th ed. Neurology and Psychiatry. Richardson M Chant C Chessman KH Finsk SW Hemstreet BA Hume AL, ed. Lenexa, KS: American College of Clinical Pharmacy ; 2012: 45-64.
25. Melkersson K. Serum creatine kinase levels in chronic psychosis patients - a comparison between atypical and conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30 (7). 1277-1282
26. Leonhauser M. Antipsychotics: multiple indications help drive growth. Pharma Marketers. 2012 ; 360: 22-24
27. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011 ; 20 (2). 177-184
28. Yoshikawa H, Watanabe T, Abe T, et al. Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child. Brain Develop. 2000 ; 22 (4). 256-258
29. Marsh SJ, Dolson GM. Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. Ren Fail. 1995 ; 17 (4). 475-478
30. Marinella MA. Rhabdomyolysis associated with haloperidol without evidence of NMS. Ann Pharmacother. 1997 ; 31 (7-8). 927-928
31. Karre PR, Gujral J, Rodriguez E. Rhabdomyolysis with erratic serum creatine phosphokinase levels: intramuscular injection of haloperidol decanoate. BMJ Case Rep. 2009 ;: 2009
32. Nankivell BJ, Bhandari PK, Koller LJ. Rhabdomyolysis induced by thioridazine. BMJ. 1994 ; 309 (6951). 378
33. Thase ME, Shostak M. Rhabdomyolysis complicating rapid intramuscular neuroleptization. J Clin Psychopharmacol. 1984 ; 4 (1). 46-48
34. Tam CW, Olin BR, Ruiz AE. Loxapine-associated rhabdomyolysis and acute renal failure. Arch Intern Med. 1980 ; 140 (7). 975-976
35. Caruana RJ, Dilworth LR, Williford PM. Acute rhabdomyolysis associated with overdose of lorazepam, perphenazine and amitriptyline. N C Med J. 1983 ; 44 (1). 18-19
36. Chang KY, Wu YF. Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci. 2011 ; 22 (3). E51
37. Marzetti E, Bocchino L, Teramo S, et al. Rhabdomyolysis in a patient on aripiprazole with traumatic hip prosthesis luxation. J Neuropsychiatry Clin Neurosci. 2012 ; 24 (4). E40 - E41
38. Koren W, Koren E, Nacasch N, et al. Rhabdomyolysis associated with clozapine treatment in a patients with decreased calcium-potassium permeability of cell membranes. Clin Neuropharmacol. 1998 ; 21 (4). 262-264
39. Tseng KC, Hwang TJ. Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium. J Clin Psychopharmacol. 2009 ; 29 (4). 398-399
40. Baumgart U, Schmid R, Spiel H. Olanzapine-induced acute rhabdomyolysis. Pharmacopsychiatry. 2005 ; 38 (1). 36-37
41. Shuster J. Olanzapine and rhabdomyolysis. Nursing. 2000 ; 30 (9). 87
42. Rosebraugh CJ, Flockhart DA, Yasuda SU, et al. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001 ; 35 (9). 1020-1023
43. Hung CF, Huang TY, Lin PY. Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. Gen Hosp Psychiatry. 2009 ; 31 (4). 376-378
44. Karakaya P, Yis U, Kurul SH, et al. Rhabdomyolysis associated with olanzapine treatment in a child with autism. Ped Emerg Care. 2010 ; 26 (1). 41-42
45. Strawn JR, Adler CM, Strakowski SM, et al. Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine. J Child Adolesc Psychopharmacol. 2008 ; 18 (1). 116-118
46. Stephani C, Trenkwalder C. Rhabdomyolysis after low dose quetiapine in a patient with Parkinson's disease with drug-induced psychosis: a case report. Mov Disord. 2010 ; 25 (6). 790-791
47. Himmerich H, Ehrlinger M, Hackenberg M, et al. Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. J Clin Psychopharmacol. 2006 ; 26 (6). 676-677
48. Velasco Montes J, Orinuela Gonzalez I, Sanjuan Lopex AZ. Rhabdomyolysis secondary to quetiapine. Actas Esp Psiquiatr. 2012 ; 40 (2). 97-98
49. Ceri M, Unverdi S. Comment on: low dose quetiapine-induced severe rhabdomyolysis. Ren Fail. 2011 ; 33 (4). 463-464
50. Dickmann JRM, Dickmann LM. An uncommonly recognized cause of rhabdomyolysis after quetiapine intoxication. Am J Emerg Med. 2010 ; 28 (9). 1060-1061
51. Smith RP, Puckett BN, Crawford J, et al. Quetiapine overdose and sever rhabdomyolysis. J Clin Psychopharmacol. 2004 ; 24 (3). 343
52. Liolios A, Sentissi O. Rhabdomyolysis following acute extended-release quetiapine poisoning: as case report. Case Rep Psychiatry. 2012;2012 ;: 347421
53. Webber MA, Mahmud W, Lightfoot JD, et al. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol. 2004 ; 18 (3). 432-434
54. Giner V, Munoz R, Redon J. Risperidone and severe cerivastatin induced rhabdomyolysis. J Int Med. 2002 ; 251 (2). 177-178
55. Vives S, Batlle M, Montane E, et al. Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogenic stem cell transplantation patient. Med Clin Barc. 2008 ; 131 (17). 676
56. Patier JL, Ferrere F, Moreno Cobo MA, et al. Rhabdomyolysis caused by the association of simvastatin and risperidone. Med Clin Barc. 2007 ; 129 (11). 439
57. Zink M, Knopf U, Argiriou S, et al. A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. J Clin Psychiatry. 2006 ; 67 (5). 835
58. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry. 2002 ; 159 (8). 1435
59. Star K, Iessa N, Almandil NB, et al. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis. J Child Adoles Psychopharmacol. 2012 ; 22 (6). 440-451
60. Linares LA, Golomb BA, Jaojoco JA, et al. Modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening. Curr Drug Saf. 2009 ; 4 (3). 181-187
61. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Res. 2012 ; 138 (1). 18-28
62. Padurangi AK, Vernon JT Polypharmacy in Psychiatry Practice. Ritsner, ed. Netherlands: M.S. Springer Science + Business Medial ; 2013: 11-29.
63. Goren JL, Meterko M, Williams S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013 ; 64 (6). 527-533
64. Waring WS, Wrate J, Bateman DN. Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol. 2006 ; 25 (12). 735-740